4579.T
RaQualia Pharma Inc. [4579.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
4579.T Stock Summary
Top 10 Correlated ETFs
4579.T
Top 10 Correlated Stocks
4579.T
In the News
4579.T Financial details
4579.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 36.55 | 82.71 | 52.85 | 132.5 | 139.16 | |
| Net income per share | -54.23 | 0.26 | -28.97 | 36.07 | 34.5 | |
| Operating cash flow per share | -19.83 | -25.78 | -13.8 | 17.47 | 70.58 | |
| Free cash flow per share | -30.69 | -30.37 | -21.27 | 12.44 | 69.06 | |
| Cash per share | 90.31 | 106.86 | 100.88 | 126.91 | 187.23 | |
| Book value per share | 189.36 | 224.42 | 191.46 | 228.51 | 262.14 | |
| Tangible book value per share | 187.69 | 222.85 | 189.88 | 226.9 | 260.98 | |
| Share holders equity per share | 189.36 | 224.42 | 191.46 | 228.51 | 262.14 | |
| Interest debt per share | 0.15 | 0.12 | 2.19 | 1.93 | 10.89 | |
| Market cap | 21.94B | 27.61B | 20.95B | 24.6B | 25.83B | |
| Enterprise value | 20.27B | 25.44B | 19.6B | 22.29B | 22.38B | |
| P/E ratio | -19.86 | 5.17K | -34.52 | 32.55 | 35.71 | |
| Price to sales ratio | 29.46 | 16.21 | 18.92 | 8.86 | 8.85 | |
| POCF ratio | -54.3 | -52.01 | -72.44 | 67.21 | 17.45 | |
| PFCF ratio | -35.09 | -44.16 | -47.02 | 94.39 | 17.84 | |
| P/B Ratio | 5.69 | 5.98 | 5.22 | 5.14 | 4.7 | |
| PTB ratio | 5.69 | 5.98 | 5.22 | 5.14 | 4.7 | |
| EV to sales | 27.22 | 14.94 | 17.7 | 8.03 | 7.67 | |
| Enterprise value over EBITDA | -21.67 | 222.73 | -48.55 | 21.92 | 21.21 | |
| EV to operating cash flow | -50.17 | -47.92 | -67.78 | 60.9 | 15.12 | |
| EV to free cash flow | -32.42 | -40.69 | -43.99 | 85.54 | 15.45 | |
| Earnings yield | -0.05 | 0 | -0.03 | 0.03 | 0.03 | |
| Free cash flow yield | -0.03 | -0.02 | -0.02 | 0.01 | 0.06 | |
| Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.04 | |
| Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.04 | |
| Net debt to EBITDA | 1.78 | -19.02 | 3.34 | -2.27 | -3.27 | |
| Current ratio | 11.93 | 16.75 | 15.18 | 10 | 9.77 | |
| Interest coverage | 0 | 0 | -1.11K | 486.84 | 144.49 | |
| Income quality | 0.37 | -19.44 | 0.55 | 0.42 | 1.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.88 | 0.35 | 0.47 | 0.22 | 0.2 | |
| Research and developement to revenue | 1.44 | 0.51 | 0.84 | 0.41 | 0.43 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to operating cash flow | 0.55 | 0.18 | 0.54 | -0.29 | -0.02 | |
| Capex to revenue | -0.3 | -0.06 | -0.14 | -0.04 | -0.01 | |
| Capex to depreciation | -1.76 | -0.67 | -1.26 | -0.74 | -0.22 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 480.67 | 36.2 | 353.28 | 430.65 | 451.08 | |
| ROIC | -0.29 | 0 | -0.14 | 0.12 | 0.12 | |
| Return on tangible assets | -0.27 | 0 | -0.14 | 0.15 | 0.12 | |
| Graham Net | 83.88 | 126.47 | 111.68 | 152.82 | 179.8 | |
| Working capital | 1.8B | 2.88B | 2.65B | 3.6B | 4.33B | |
| Tangible asset value | 3.82B | 4.59B | 3.98B | 4.75B | 5.47B | |
| Net current asset value | 1.77B | 2.85B | 2.59B | 3.56B | 4.06B | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0.04 | |
| Average receivables | 390.99M | 451.9M | 719.96M | 964.6M | 1.06B | |
| Average payables | 992K | 17.15M | 38.06M | 43.91M | 87.03M | |
| Average inventory | 5.83M | 6M | 6.02M | 8.54M | 9.52M | |
| Days sales outstanding | 39.88 | 176.28 | 203.54 | 172.46 | 100.16 | |
| Days payables outstanding | 0 | 47.63 | 110.63 | 52.35 | 201.84 | |
| Days of inventory on hand | 26.53 | 7.64 | 17.3 | 12 | 13.4 | |
| Receivables turnover | 9.15 | 2.07 | 1.79 | 2.12 | 3.64 | |
| Payables turnover | 0 | 7.66 | 3.3 | 6.97 | 1.81 | |
| Inventory turnover | 13.76 | 47.78 | 21.1 | 30.4 | 27.25 | |
| ROE | -0.29 | 0 | -0.15 | 0.16 | 0.13 | |
| Capex per share | -10.86 | -4.58 | -7.46 | -5.03 | -1.52 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 13.76 | 5.68 | 48.34 | 17.17 | 29.78 | |
| Net income per share | 7.33 | -0.03 | 12.22 | -6.88 | 8.04 | |
| Operating cash flow per share | 2.95 | 4.26 | 25.15 | -9.76 | -23.35 | |
| Free cash flow per share | 2.79 | 4.08 | 24.9 | -11.32 | -28.07 | |
| Cash per share | 41.43 | 46.63 | 187.23 | 210.01 | 176.52 | |
| Book value per share | 65.31 | 65.16 | 262.14 | 289.74 | 300.65 | |
| Tangible book value per share | 64.95 | 64.82 | 260.98 | 288.02 | 299.07 | |
| Share holders equity per share | 65.31 | 65.16 | 262.14 | 289.74 | 300.65 | |
| Interest debt per share | 3.16 | 3.01 | 10.69 | 12.15 | 11.49 | |
| Market cap | 56.76B | 84.06B | 25.83B | 18.08B | 15.97B | |
| Enterprise value | 53.85B | 80.74B | 22.38B | 14.07B | 12.67B | |
| P/E ratio | 24.04 | -9.04K | 25.21 | -30.46 | 22.97 | |
| Price to sales ratio | 51.23 | 183.88 | 25.48 | 48.8 | 24.82 | |
| POCF ratio | 239.32 | 245.11 | 48.99 | -85.82 | -31.65 | |
| PFCF ratio | 252.46 | 255.71 | 49.48 | -74.02 | -26.33 | |
| P/B Ratio | 10.79 | 16.02 | 4.7 | 2.89 | 2.46 | |
| PTB ratio | 10.79 | 16.02 | 4.7 | 2.89 | 2.46 | |
| EV to sales | 48.6 | 176.63 | 22.08 | 37.97 | 19.69 | |
| Enterprise value over EBITDA | 65.51 | -118.92K | 87.75 | -189.51 | 58.06 | |
| EV to operating cash flow | 227.04 | 235.45 | 42.45 | -66.78 | -25.11 | |
| EV to free cash flow | 239.5 | 245.63 | 42.87 | -57.6 | -20.89 | |
| Earnings yield | 0.01 | 0 | 0.01 | -0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0.02 | -0.01 | -0.04 | |
| Debt to equity | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | -3.54 | 4.88K | -13.54 | 54.03 | -15.11 | |
| Current ratio | 10.56 | 13.05 | 9.77 | 14.1 | 14.77 | |
| Interest coverage | 358.97 | -29.9 | 123.78 | -72.26 | 56.22 | |
| Income quality | 0.31 | -102.34 | 2.96 | 1.91 | -3.44 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.29 | 0.17 | 0.41 | 0.25 | |
| Research and developement to revenue | 0.24 | 0.68 | 0.4 | 0.72 | 0.52 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to operating cash flow | -0.05 | -0.04 | -0.01 | 0.16 | 0.2 | |
| Capex to revenue | -0.01 | -0.03 | -0.01 | -0.09 | -0.16 | |
| Capex to depreciation | -0.33 | -0.37 | -0.13 | -1.08 | -2.5 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 103.81 | 6.51 | 268.46 | 211.74 | 233.27 | |
| ROIC | 0.09 | -0.01 | 0.05 | -0.02 | 0.01 | |
| Return on tangible assets | 0.1 | 0 | 0.04 | -0.02 | 0.02 | |
| Graham Net | 43.52 | 46.13 | 179.8 | 199.74 | 188.77 | |
| Working capital | 4.1B | 4.24B | 4.33B | 4.92B | 4.86B | |
| Tangible asset value | 5.23B | 5.22B | 5.47B | 6.21B | 6.46B | |
| Net current asset value | 3.86B | 3.99B | 4.06B | 4.59B | 4.51B | |
| Invested capital | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | |
| Average receivables | 886.58M | 934.42M | 772.89M | 720.65M | 965M | |
| Average payables | 57.29M | 63.07M | 99M | 94.84M | 64.98M | |
| Average inventory | 8.96M | 8.76M | 8.84M | 8.53M | 8.47M | |
| Days sales outstanding | 91.29 | 146.68 | 71.09 | 155.6 | 180.32 | |
| Days payables outstanding | 98.45 | 99.3 | 181.22 | 93.31 | 97.87 | |
| Days of inventory on hand | 14.62 | 13.03 | 12.03 | 12.98 | 11.98 | |
| Receivables turnover | 0.99 | 0.61 | 1.27 | 0.58 | 0.5 | |
| Payables turnover | 0.91 | 0.91 | 0.5 | 0.96 | 0.92 | |
| Inventory turnover | 6.15 | 6.91 | 7.48 | 6.94 | 7.51 | |
| ROE | 0.11 | 0 | 0.05 | -0.02 | 0.03 | |
| Capex per share | -0.15 | -0.18 | -0.25 | -1.56 | -4.72 |
4579.T Frequently Asked Questions
What is RaQualia Pharma Inc. stock symbol ?
RaQualia Pharma Inc. is a JP stock and trading under the symbol 4579.T
What is RaQualia Pharma Inc. stock quote today ?
RaQualia Pharma Inc. stock price is $736 today.
Is RaQualia Pharma Inc. stock public?
Yes, RaQualia Pharma Inc. is a publicly traded company.
Company Profile
- Volume Average 134.73K
- Market Capitalization 15.63B
- Employee 65
- CEO Mr. Hirobumi Takeuchi
- Headquarters Nagoya,JP
- IPO Date 2011-07-20
-
Website
https://www.raqualia.co.jp 
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
